126 related articles for article (PubMed ID: 22095373)
1. Different HER2 protein expression profiles aid in the histologic differential diagnosis between urothelial carcinoma in situ (CIS) and non-CIS conditions (dysplasia and reactive atypia) of the urinary bladder mucosa.
Gunia S; Koch S; Hakenberg OW; May M; Kakies C; Erbersdobler A
Am J Clin Pathol; 2011 Dec; 136(6):881-8. PubMed ID: 22095373
[TBL] [Abstract][Full Text] [Related]
2. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions.
Schwarz S; Rechenmacher M; Filbeck T; Knuechel R; Blaszyk H; Hartmann A; Brockhoff G
J Clin Pathol; 2008 Mar; 61(3):272-7. PubMed ID: 17693577
[TBL] [Abstract][Full Text] [Related]
3. Lewis(y) antigen (blood group 8, BG8) is a useful marker in the histopathological differential diagnosis of flat urothelial lesions of the urinary bladder.
Gunia S; Kakies C; May M; Koch S; Erbersdobler A
J Clin Pathol; 2011 Aug; 64(8):672-6. PubMed ID: 21512109
[TBL] [Abstract][Full Text] [Related]
4. Scoring the percentage of Ki67 positive nuclei is superior to mitotic count and the mitosis marker phosphohistone H3 (PHH3) in terms of differentiating flat lesions of the bladder mucosa.
Gunia S; Kakies C; Erbersdobler A; Koch S; May M
J Clin Pathol; 2012 Aug; 65(8):715-20. PubMed ID: 22554964
[TBL] [Abstract][Full Text] [Related]
5. The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138, and Her2/Neu.
Jung S; Wu C; Eslami Z; Tanguay S; Aprikian A; Kassouf W; Brimo F
Ann Diagn Pathol; 2014 Feb; 18(1):27-32. PubMed ID: 24321464
[TBL] [Abstract][Full Text] [Related]
6. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
[TBL] [Abstract][Full Text] [Related]
7. Flat intraepithelial lesions of the urinary bladder.
Cheng L; Cheville JC; Neumann RM; Bostwick DG
Cancer; 2000 Feb; 88(3):625-31. PubMed ID: 10649257
[TBL] [Abstract][Full Text] [Related]
8. [FISH analysis in the differential diagnosis of flat urothelial lesions using tissue microarrays].
Schwarz S; Rechenmacher M; Lottner C; Brockhoff G; Hartmann A; Langer S; Knüchel R
Verh Dtsch Ges Pathol; 2004; 88():184-93. PubMed ID: 16892551
[TBL] [Abstract][Full Text] [Related]
9. p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ.
Yin M; Bastacky S; Parwani AV; McHale T; Dhir R
Hum Pathol; 2008 Apr; 39(4):527-35. PubMed ID: 18234280
[TBL] [Abstract][Full Text] [Related]
10. The pagetoid variant of bladder urothelial carcinoma in situ A clinicopathological study of 11 cases.
Lopez-Beltran A; Luque RJ; Moreno A; Bollito E; Carmona E; Montironi R
Virchows Arch; 2002 Aug; 441(2):148-53. PubMed ID: 12189504
[TBL] [Abstract][Full Text] [Related]
11. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases.
Guo CC; Fine SW; Epstein JI
Am J Surg Pathol; 2006 Jul; 30(7):883-91. PubMed ID: 16819332
[TBL] [Abstract][Full Text] [Related]
13. CIS is a surrogate marker of genetic instability and field carcinogenesis in the urothelial mucosa.
Palmeira C; Lameiras C; Amaro T; Lima L; Koch A; Lopes C; Oliveira PA; Santos L
Urol Oncol; 2011; 29(2):205-11. PubMed ID: 19854077
[TBL] [Abstract][Full Text] [Related]
14. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of fibroblast growth factor receptor 3 and epidermal growth factor receptors, in association with Raf-1, in urothelial dysplasia and carcinoma in situ after the Chernobyl accident.
Romanenko AM; Morimura K; Kinoshita A; Wanibuchi H; Takahashi S; Zaparin WK; Vinnichenko WI; Vozianov AF; Fukushima S
Cancer Sci; 2006 Nov; 97(11):1168-74. PubMed ID: 16965395
[TBL] [Abstract][Full Text] [Related]
16. Urothelial dysplasia of the bladder: diagnostic features and clinical significance.
Lopez-Beltran A; Montironi R; Vidal A; Scarpelli M; Cheng L
Anal Quant Cytopathol Histpathol; 2013 Jun; 35(3):121-9. PubMed ID: 24344498
[TBL] [Abstract][Full Text] [Related]
17. An objective morphologic parameter to aid in the diagnosis of flat urothelial carcinoma in situ.
Milord RA; Lecksell K; Epstein JI
Hum Pathol; 2001 Sep; 32(9):997-1002. PubMed ID: 11567231
[TBL] [Abstract][Full Text] [Related]
18. HER2 protein overexpression and gene amplification in upper urinary tract transitional cell carcinoma: systematic analysis applying tissue microarray technique.
Langner C; Gross C; Rehak P; Ratschek M; Rüschoff J; Zigeuner R
Urology; 2005 Jan; 65(1):176-80. PubMed ID: 15667899
[TBL] [Abstract][Full Text] [Related]
19. Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications.
Krüger S; Lange I; Kausch I; Feller AC
Anticancer Res; 2005; 25(1A):263-71. PubMed ID: 15816547
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of Her2/neu overexpression in urothelial carcinomas.
Alexa A; Baderca F; Zăhoi DE; Lighezan R; Izvernariu D; Raica M
Rom J Morphol Embryol; 2010; 51(2):277-82. PubMed ID: 20495743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
